Sara Grater
Nurse Practitioner · Akron, OHNPI 1831573799
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 1,327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 6.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,327 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Biogen$1K
- Jazz Pharmaceuticals Inc.$1K
- SK Life Science, Inc.$1K
- UCB, Inc.$1K
- plus $15K from 54 others
What the payments were for
- Consulting fees$3001%
- Food & beverage$22,32295%
- Education$8654%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,488 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 19 | $22,748 |
| EliquisApixaban | 27 | $16,082 |
| BelsomraSuvorexant | 13 | $6,526 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 102 | $5,318 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 11 | $3,665 |
| Entacapone | 21 | $3,622 |
| Levetiracetam | 95 | $2,248 |
| Pyridostigmine Bromide | 21 | $1,507 |
| Gabapentin | 33 | $1,338 |
| Memantine Hcl | 53 | $1,243 |
| Baclofen | 27 | $984 |
| Oxcarbazepine | 13 | $948 |
| Lacosamide | 14 | $862 |
| Cilostazol | 27 | $663 |
| Donepezil Hcl | 46 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $1,589 | $22,74819 claims |
| PfizerEliquis | $317 | $16,08227 claims |
| MerckBelsomra | $72 | $6,52613 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $50 | $1,50721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Akron
- Julia GoldenAkron$11K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.